Developing a new treatment for giardiasis
Development of PTLS-209 for treatment for giardiasis
This study is testing a new treatment called PTLS-209 for giardiasis, a pesky infection that causes bad diarrhea, especially in kids, to see if it can work better and have fewer side effects than current options.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Primetime Life Sciences, LLC NIH-funded |
| Lab location | 1 site (Germantown, United States) |
| Project ID | NIH-10892308 on NIH RePORTER |
What this research studies
This research focuses on creating a new treatment for giardiasis, a parasitic infection caused by Giardia lamblia that leads to severe diarrhea, especially in children. Current treatments are often ineffective and can have undesirable side effects, with about 20% of cases failing to respond. The researchers are working on a compound called PTLS-209, which has shown promise in laboratory tests for its ability to effectively target the parasite while minimizing toxicity and improving stability. This project aims to optimize PTLS-209 to ensure it can be safely used in patients, particularly in vulnerable populations such as children.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under 11 years old who are suffering from giardiasis or are at risk of infection.
Not a fit: Patients with giardiasis who are older than 11 years or those who do not have a confirmed diagnosis of the infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and safer treatment option for giardiasis, potentially reducing the incidence of severe diarrhea and its complications in affected patients.
How similar studies have performed: Previous research has shown promise in developing new treatments for giardiasis, but the specific approach with PTLS-209 is novel and has not been extensively tested in humans.
Where this research is happening
Germantown, United States
- Primetime Life Sciences, LLC — Germantown, United States (Active)
Researchers
- Principal investigator: Padia, Janak K — Primetime Life Sciences, LLC
- Study coordinator: Padia, Janak K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.